Confirming a potential role in cancer, IP5 has been shown to activate HDAC1 and HDAC3, thereby likely contributing to epigenetic regulation of cancer progression [374,375] and to act as a key second messenger in cancer-associated Wnt3a signalling, including the inhibition of glycogen synthase kinase-3beta (GSK3β) and subsequent accumulation of beta-catenin [376]. The gene discussed is WNT3A; the disease is cancer.